Vishvinder Sharma, MD
Gastroenterology · North Las Vegas, NVNPI 1538260468
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,044 of the $4,854 with a category attached, or 62.7%. 29 manufacturers reported payments, led by Medtronic at 33.8% of the total. 2025 is the largest year on record at $1,609, 3.6 times the $445 reported in 2019.
Across 133 payments — averaging $36.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- AbbVie$691
- Johnson & Johnson$570
- Boston Scientific$392
- Intra-sana Laboratories$179
- Mallinckrodt Hospital Products Inc.$151
- plus $1K from 23 others
Across 20 payments — averaging $5311.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Phathom Pharmaceuticals, Inc.$52K
- Janssen Research & Development, LLC$45K
- Braintree Laboratories, Inc.$10K
What the payments were for
- Travel & lodging$1,51231%
- Food & beverage$3,04463%
- Education$1984%
- Gifts$1002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 8 | $1,642 |
| AbbVie | 32 | $691 |
| Johnson & Johnson | 32 | $570 |
| Boston Scientific | 7 | $392 |
| Intra-sana Laboratories | 4 | $179 |
| Mallinckrodt Hospital Products Inc. | 2 | $151 |
| Pfizer | 6 | $125 |
| Intercept Pharmaceuticals, Inc. | 1 | $125 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $112 |
| Regeneron Healthcare Solutions, Inc. | 4 | $108 |
| Gilead | 1 | $91 |
| Sanofi | 3 | $91 |
| Merck | 3 | $67 |
| Celltrion USA Inc. | 3 | $62 |
| Covidien LP | 1 | $60 |
| QOL Medical, LLC | 6 | $58 |
| Ferring Pharmaceuticals Inc. | 2 | $43 |
| Aimmune Therapeutics, Inc. | 2 | $35 |
| Madrigal Pharmaceuticals | 1 | $34 |
| Organon | 1 | $28 |
| Phathom Pharmaceuticals, Inc. | 1 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Redhill Biopharma Inc. | 1 | $23 |
| Nestle Healthcare Nutrition Inc. | 1 | $22 |
| Ironwood Pharmaceuticals, Inc | 1 | $21 |
| Amgen | 1 | $20 |
| Novo Nordisk | 1 | $19 |
| Bristol Myers Squibb | 1 | $18 |
| Ardelyx, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GI Genius$623
- TERLIVAZ$133
- OCALIVA$125
- Watchman$100
- Reltone 200 Mg$100
- Reltone 400 Mg$100
How this compares
$4,854 in reported general payments places this provider in the 60th percentile of 103 gastroenterology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 19 | $482,732 |
| Humira(Cf) PenAdalimumab | 13 | $104,447 |
| RenflexisInfliximab-Abda | 14 | $38,024 |
| CreonLipase/Protease/Amylase | 17 | $32,734 |
| VemlidyTenofovir Alafenamide | 11 | $15,945 |
| LinzessLinaclotide | 20 | $13,827 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 27 | $4,391 |
| Mesalamine | 19 | $1,462 |
| Omeprazole | 87 | $1,081 |
| Pantoprazole Sodium | 103 | $1,025 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 46 | $651 |
| Budesonide DrBudesonide | 12 | $571 |
| LoperamideLoperamide Hcl | 34 | $547 |
| Famotidine | 37 | $502 |
| Esomeprazole Magnesium | 14 | $471 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $570 | $482,73219 claims |
| AbbVieCreon, Linzess | $691 | $46,56137 claims |
| OrganonRenflexis | $28 | $38,02414 claims |
| GileadVemlidy | $91 | $15,94511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 103 gastroenterology providers in Nevada.
Other gastroenterology in North Las Vegas
- Yasser SaloumNorth Las Vegas$49K
- Joseph FayadNorth Las Vegas$4K
- Christian StoneLas Vegas$1.1M
- Rajat SoodHenderson$258K
- James HanLas Vegas$47K
- Filippo CremoniniLas Vegas$36K
- Vijay JayaramanLas Vegas$28K
- Gary ChenLas Vegas$27K
- David ShihLas Vegas$26K
- Noel FajardoLas Vegas$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.